Recent Updates
Recently added Catalysts

KLN-1010

Phase 1

Multiple Myeloma in Relapse | Small molecule | Oncology |cbdMD, Inc.|Last Updated: Aug 28, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment70

FDA Designations

No designations recorded

Clinical trial landscape

KLN-1010 · 1 trial · 14 indications

Phase 1 1
NCT07075185A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple MyelomaMultiple Myeloma in Relapse
RECRUITING70 Analytics
PHASE1RECRUITING
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma in Relapse
NCT0707518570
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence and severity of treatment-emergent adverse events (TEAEs), including dose-limiting toxicities (DLTs), and/or establish the recommended Phase 2 Dose
Up to 15 years from dosing of KLN-1010

All adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) or American Society for Transplantation and Cell Therapy (ASTCT) criteria

Secondary Endpoints

Pharmacokinetics of KLN-1010 after dosing.
Up to two years after dosing with study drug.
Pharmacokinetics of KLN-1010 (Tmax).
Up to two years after infusion with study drug.
Pharmacokinetics of KLN-1010 Area Under the Curve (AUC)
Up to two years after infusion with study drug.
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
KLN-1010EXPERIMENTALDrug: KLN-1010 specified dose given once

Interventions

NameTypeDescription
KLN-1010DRUGGiven at specified dose one time
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites11

Inclusion Criteria: * Participants must have relapsed and refractory multiple myeloma (RRMM) with measurable disease * Participants must have received at least 3 prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and CD38-directed monoclonal antibody * Pa...

Countries:United StatesAustralia
Unlock Eligibility Criteria